Royalty Pharma (RPRX) Long-Term Investments (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Long-Term Investments data on file, last reported at $265.7 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 88.33% year-over-year to $265.7 million; the trailing twelve-month figure through Mar 2026 stood at $265.7 million (up 88.33% YoY), and the FY2025 full-year result was $171.3 million, down 54.85% from the prior year.
• Long-Term Investments improved to $265.7 million in Q1 2026, from $171.3 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $409.9 million in Q3 2022 to a low of $63.0 million in Q2 2022.
• A 5-year average of $253.6 million and a median of $267.2 million in 2023 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments slumped 68.89% in 2022 and surged 126.67% in 2023, its largest moves.
• Tracing RPRX's Long-Term Investments over 5 years: stood at $226.3 million in 2022, then jumped by 66.1% to $375.9 million in 2023, then gained by 0.94% to $379.4 million in 2024, then tumbled by 54.85% to $171.3 million in 2025, then jumped by 55.1% to $265.7 million in 2026.
• Business Quant data shows RPRX's Long-Term Investments at $265.7 million in Q1 2026, $171.3 million in Q4 2025, and $291.0 million in Q3 2025.